100 days ago • Posted by Charles-Henry Monchau

Covid vaccine: the "bear" case

VIR management, an anti-body manufacturer, articulated a bear case for covid-19 vaccine: 1) the real-world efficacy rate is likely to vary from the headline figure reported, and the inevitable distribution and uptake challenges suggest that COVID-19 will remain an issue until herd immunity mounts or perhaps may even become endemic similar to the seasonal flu; 2) We have yet to see how vaccine efficacy rates breakdown across populations, and note that there may still be a need for certain groups including the elderly where earlier trials noted a lower rate of injection site reaction that might be indicative of a lower vaccine response in these subjects in general (source: Goldman Sachs Trading desk, The Market Ear)

The bear case for a vaccine